Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
25.40
+0.14 (+0.55%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pfizer
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Pfizer Provides Full-Year 2024 Guidance
December 13, 2023
From
Pfizer Inc.
Via
Business Wire
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
December 12, 2023
From
Pfizer Inc.
Via
Business Wire
FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B
December 11, 2023
From
Pfizer Inc.
Via
Business Wire
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
December 09, 2023
From
Pfizer Inc.
Via
Business Wire
Pfizer Inc. (NYSE: PFE) is One of Friday Morning’s Most Active Stocks
December 01, 2023
Via
Investor Brand Network
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
December 08, 2023
From
Pfizer Inc.
Via
Business Wire
A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene
December 07, 2023
Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.
Via
SBWire
Neuropsychiatric Disorders and Treatment Market Projected to Show Strong Growth: Astrazeneca, AviadoBio, Astellas Pharma
December 07, 2023
Get an extensive Neuropsychiatric Disorders And Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.
Via
SBWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Pneumococcal Pneumonia Can Be Life-Threatening. Here’s What to Know
November 15, 2023
Via
StatePoint Media
Generis and Ideagen Announce Integration to Advance Information Management Processes in Regulated Industries
December 13, 2023
LONDON - Dec. 13, 2023 - PRLog -- Generis, developer of the CARA Platform for data, content, and business process management, and Ideagen PleaseReview today announced their integration partnership to...
Via
PRLog
Simply Good Foods: Winner in the Ozempic Weight-Loss Trend
December 06, 2023
Nutritional food and snacks producer The Simply Good Foods Co. (NASDAQ: SMPL) has seen its shares rocket higher on the weight-loss medication
Via
MarketBeat
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
December 05, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Ozempic vs. Mounjaro:: Battle of the bulge
December 04, 2023
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs, led by the popularity of Ozempic. Celebrity usage
Via
MarketBeat
Exposures
Product Safety
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
December 01, 2023
From
Pfizer Inc.
Via
Business Wire
Allergy Treatment Market Know Faster Growing Segments Now: Akorn, Pfizer, Novartis, Mylan N.V
November 30, 2023
Global Allergy Treatment Market Breakdown by Application (Hospitals, Specialty Clinics, Homecare, Others) by Type (Eye Allergy, Food Allergy, Skin Allergy, Asthma, Rhinitis, Others) by Treatment...
Via
SBWire
Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030
November 29, 2023
Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis.
Via
SBWire
J&J, Gilead, BMS: A look at undervalued dividend payers
November 29, 2023
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown
Via
MarketBeat
New Partnership Between Generis And Risetime Provides Easy and Compliant Information Management for Cosmetics Industry
November 29, 2023
CHICAGO - Nov. 29, 2023 - PRLog -- Generis, developer of the CARA Platform for data, content, and business process management, and Risetime, provider of digital content management services for the...
Via
PRLog
Exposures
Product Safety
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
November 28, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Heart Failure Drugs Market Critical Analysis with Expert Opinion : Johnson & Johnson, Pfizer, Roche
November 24, 2023
Global Heart Failure Drugs Market Breakdown by Application (Reduced Ejection Fraction, Preserved Ejection Fraction) by Type (ACE inhibitors, Beta Blockers, Diuretics, Sacubitril Valsartan, Others) by...
Via
SBWire
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 21, 2023
From
Pfizer Inc.
Via
Business Wire
Safeguard your portfolio with these three bargain stocks
November 21, 2023
Nobody is sure about the market's direction today; these are the stocks that can offer you a good chunk of growth at very little downside risk
Via
MarketBeat
2 overlooked stocks that crushed earnings but traded lower
November 20, 2023
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results
Via
MarketBeat
Exposures
Product Safety
Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes $200 Billion GLP-1 Market with its DehydraTECH(TM) Technology
November 14, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
4 high yields near 52-week lows worth looking at
November 14, 2023
These stocks trading near 52-week lows provide high-yielding values for buy-and-hold investors; most are at or near their bottom and may rebound soon
Via
MarketBeat
Exposures
COVID-19
MarketBeat Week in Review – 11/6 - 11/10
November 11, 2023
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance
November 09, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:GILD),(NYSE:MRK),(NYSE:PFE) EQNX::TICKER_END
Via
FinancialNewsMedia
Why you can make Vertex Pharmaceuticals a buy on any pullback
November 08, 2023
Vertex stock is off its all-time highs after a slight miss on revenue, but the company's robust pipeline gives investors a reason to watch VRTX stock closely
Via
MarketBeat
Exposures
COVID-19
GSK is a remedy for the winter investment blahs
November 07, 2023
Pharma stock GSK is a remedy for the winter blahs with a low beta, a high yield, and value for investors. Sales of new drug Arexvy underpin results.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Product Safety
Pfizer and Sanofi shares fall, which one to scoop up?
November 07, 2023
Pharmaceutical stocks aren't having a banner year; notably, two large pharmaceutical companies recently plunged to 52-week lows
Via
MarketBeat
Exposures
COVID-19
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.